Author Topic: Emerging evidence on the selective use of AHSCT[stem cells] in MS  (Read 88 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9480
  • MS diagnosed 1980
  • Location: Pacific Northwest

Looking at the "optimal profile" for people who might benefit from AHSCT (autologous hematopoietic stem cell transplantation), I'd say that the use of it will be very selective.

RRMS or progressive MS for a short timeRelapses in the previous year, indicating recent clinical inflammatory activityRecent inflammatory activity, as identified by magnetic resonance imagingAge less than 45 yearsDuration of disease of 10 years or lessDisability designated as low to moderateFailure of no more than 2 prior disease-modifying therapiesNo clinically significant comorbiditiesCognitive ability to agree to and adhere to recommended care, especially in immunocompromised phases.

"Emerging evidence on the selective use of AHSCT in MS"--from MedPage Today, October 29, 2018:
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post March 16, 2017, 03:48:27 pm
by agate
0 Replies
Last post August 15, 2019, 09:21:51 pm
by agate
1 Replies
Last post May 01, 2021, 09:36:11 pm
by agate
0 Replies
Last post October 26, 2021, 09:06:40 pm
by agate
2 Replies
Last post January 05, 2023, 08:52:50 pm
by agate